Quality Initiative Improves Thrombolysis Frequency, Timeliness
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 12, 2024 -- The U.S. nationwide quality initiative Target: Stroke (TS) is associated with improvement in thrombolysis frequency, timeliness, and outcome, according to a study published online Feb. 7 in JAMA Network Open.
Shumei Man, M.D., Ph.D., from the Cleveland Clinic, and colleagues conducted a retrospective cohort study involving patients who presented within 4.5 hours of ischemic stroke onset to examine whether the TS quality initiative was associated with improvement in thrombolysis metrics and outcomes across racial and ethnic groups. The analyses included 1,189,234 patients; 1,053,539 arrived to the hospital within 4.5 hours.
The researchers found that in all racial and ethnic groups, the unadjusted thrombolysis rates increased in the pre-TS (2003 to 2009) and TS periods (phase I: 2010 to 2013; phase II: 2014 to 2018; phase III: 2019 to 2021), from 10 to 15 percent in 2003 to 43 to 46 percent in 2021. In adjusted analyses, disparities were seen and they persisted in TS phase III, with significantly lower odds of thrombolysis receipt for Asian, Black, and Hispanic versus White patients (adjusted odds ratios, 0.85, 0.76, and 0.86, respectively). In all racial and ethnic groups, door-to-needle (DTN) times improved during TS; from 2009 to 2021, DTN times of 60 minutes or less increased from 26 to 28 percent to 66 to 72 percent. Racial and ethnic disparities were seen in adjusted analyses. Clinical outcomes improved for all racial and ethnic groups during TS.
"After adjustment for patient and hospital characteristics, Asian, Black, and Hispanic patients had lower odds of receiving thrombolysis and longer DTN times than White patients," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.